Harliku (nitisinone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	i	MEMBER'S FIRST I	NAME:		
	view (e.g., chart notes o	r lab data, to support th	 Attach any additional documenta e authorization request). Information 		
			☐ URGE	ENT	
MEMBER INFORMATIO	N				
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTI	1 :		
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE I	D NUMBER:				
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:		
PATIENT'S AUTHORIZEI AUTHORIZED REPRESE	IETHERAPEUTICS.CO	M/NOPP IF APPLICABLE):	I CAN BE FOUND AT THE		
		JWIDEK			
PRESCRIBER INFORMA	ATION				
LAST NAME:		FIRST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRES	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:		
		-			
MEDICATION OR MEDI	CAL DISPENSING INF	ORMATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:		
☐ NEW THERAPY	RENEWAL	F RENEWAL: DATE T			
DURATION OF THERAF	Y (SPECIFIC DATES):				
Continued on next page					

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.25 CAT009



Harliku (nitisinone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	IAME:			
1. HAS THE PATIENT TRIED ANY	OTHER MEDICATIONS FOR THIS	CONDITION?			
YES (if yes, complete below) NO					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Alkaptonuria(AKU) ☐ Other diagnosis:	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORI	ATION : PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION			
Is patient going to be using drug in combination with a clinical trial? 🗌 Yes 🔝 No					
Initial Request: Does patient have presence of homogentisic acid(HGA) in their urine or plasma to validate the diagnosis? Yes No Please submit documentation. Does patient have genetic confirmation of AKU? Yes No Please submit documentation.					
Is patient adhering to a tyrosine and phenylalanine low diet? Yes No					
Has the patient tried the generic nitisinone product? □ Yes □ No					
Does patient have an absolute contraindication to the generic nitisinone? Yes No *Please provide supporting chart notes.					
If the patient has tried the authorized generic nitisinone and will not be continuing it, has a U.S. FDA MedWatch Voluntary Reporting Form for adverse drug reactions (FDA Form 3500) been filed with the FDA? □ Yes □ No Please submit a copy of the completed FDA 3500 form.					
Renewal Request: Does patient continue to demonstrate a positive clinical response by showing a reduction in homogentisic acid (HGA) levels in their urine or plasma for AKU? Yes No Please submit documentation.					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					



Harliku (nitisinone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Please note: Not all drugs/diagnosis are covered required information is received.	on all plans. This request may be denied unless all
ATTESTATION: I attest the information provided i understand that the Health Plan, insurer, Medical 0	Group or its designees may perform a routine audit and y the accuracy of the information reported on this form.
information that is legally privileged. If you are not disclosure, copying, distribution, or action taken in	companying this transmission contain confidential health the intended recipient, you are hereby notified that any reliance on the contents of these documents is strictly error, please notify the sender immediately (via return nese documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909